Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Serina Therapeutics, Inc.SER · Entity 9581 | 10% owner | June 06, 2024 | February 03, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Serina Therapeutics, Inc.
Report date June 06, 2024 · Filed February 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Juv UK | 2,267,188 |
Reported balance
After 2024-06-06 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2024-06-06 · Exercise / conversion · Acquired 377,865 · Balance 2,267,188 F1: As previously reported, on March 26, 2024, the Issuer (formerly known as "AgeX Therapeutics, Inc.") completed its merger transaction with, inter alia, Serina Therapeutics, Inc. (the "Merger"). Following the closing of the Merger, the Reporting Person held 1,889,323 shares of the Issuer's common stock, which shares are included in Column 5. These shares are held by the Reporting Person's wholly owned subsidiary, JuvVentures (UK) ("Juv UK"). Additional details about the Merger and the transactions described in this report can be found in the Issuer's and the Reporting Person's previous filings with the Commission. F2: On June 6, 2024, the Reporting Person exercised 377,865 warrants at an exercise price of $13.20 per warrant (the "Original Warrants"), representing one-third of the of the Original Warrants, which were issued to the Reporting Person in connection with a warrant dividend effected on March 18, 2024, Upon such exercise, the Reporting Person was issued 377,865 shares of the Issuer's common stock and 377,865 new warrants to purchase the Issuer's common stock at an exercise price of $18.00 (the "June Warrants"). The remaining 755,728 Original Warrants were surrendered in connection with the November Agreement described in footnote 3 below. The June Warrants expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). Prior to their surrender, the Original Warrants also had an expiration date of March 26, 2028. |
| Common StockSEC Table I · non-derivative | IndirectBy Juv UK | 2,767,188 |
Reported balance
After 2024-11-27 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2024-11-27 · Grant · Acquired 500,000 · Balance 2,767,188 F1: As previously reported, on March 26, 2024, the Issuer (formerly known as "AgeX Therapeutics, Inc.") completed its merger transaction with, inter alia, Serina Therapeutics, Inc. (the "Merger"). Following the closing of the Merger, the Reporting Person held 1,889,323 shares of the Issuer's common stock, which shares are included in Column 5. These shares are held by the Reporting Person's wholly owned subsidiary, JuvVentures (UK) ("Juv UK"). Additional details about the Merger and the transactions described in this report can be found in the Issuer's and the Reporting Person's previous filings with the Commission. F3: On November 27, 2024, pursuant to certain agreements entered into among the Issuer, the Reporting Person and Juv UK dated November 26, 2024 (the "November Agreement"), the Reporting Person purchased 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and, in connection therewith, surrendered the Original Warrants and was issued 377,865 warrants to purchase shares of the Issuer's common stock (the "New Warrants"). The New Warrants have an exercise price of $18.00 per warrant, expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). On January 31, 2025, in accordance with the November Agreement, the Reporting Person purchased another 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and was issued 377,865 additional New Warrants. |
| Common StockSEC Table I · non-derivative | IndirectBu Juv UK | 3,267,188 |
Reported balance
After 2025-01-31 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2025-01-31 · Grant · Acquired 500,000 · Balance 3,267,188 F1: As previously reported, on March 26, 2024, the Issuer (formerly known as "AgeX Therapeutics, Inc.") completed its merger transaction with, inter alia, Serina Therapeutics, Inc. (the "Merger"). Following the closing of the Merger, the Reporting Person held 1,889,323 shares of the Issuer's common stock, which shares are included in Column 5. These shares are held by the Reporting Person's wholly owned subsidiary, JuvVentures (UK) ("Juv UK"). Additional details about the Merger and the transactions described in this report can be found in the Issuer's and the Reporting Person's previous filings with the Commission. F3: On November 27, 2024, pursuant to certain agreements entered into among the Issuer, the Reporting Person and Juv UK dated November 26, 2024 (the "November Agreement"), the Reporting Person purchased 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and, in connection therewith, surrendered the Original Warrants and was issued 377,865 warrants to purchase shares of the Issuer's common stock (the "New Warrants"). The New Warrants have an exercise price of $18.00 per warrant, expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). On January 31, 2025, in accordance with the November Agreement, the Reporting Person purchased another 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and was issued 377,865 additional New Warrants. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $13.20 | IndirectBy Juv UK | 755,728 |
Reported balance
After 2024-06-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-06-06 · Exercise / conversion · Disposed 377,865 · Balance 755,728 F2: On June 6, 2024, the Reporting Person exercised 377,865 warrants at an exercise price of $13.20 per warrant (the "Original Warrants"), representing one-third of the of the Original Warrants, which were issued to the Reporting Person in connection with a warrant dividend effected on March 18, 2024, Upon such exercise, the Reporting Person was issued 377,865 shares of the Issuer's common stock and 377,865 new warrants to purchase the Issuer's common stock at an exercise price of $18.00 (the "June Warrants"). The remaining 755,728 Original Warrants were surrendered in connection with the November Agreement described in footnote 3 below. The June Warrants expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). Prior to their surrender, the Original Warrants also had an expiration date of March 26, 2028. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $18.00 | IndirectBy Juv UK | 377,865 |
Reported balance
After 2024-06-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-06-06 · Grant · Acquired 377,865 · Balance 377,865 F2: On June 6, 2024, the Reporting Person exercised 377,865 warrants at an exercise price of $13.20 per warrant (the "Original Warrants"), representing one-third of the of the Original Warrants, which were issued to the Reporting Person in connection with a warrant dividend effected on March 18, 2024, Upon such exercise, the Reporting Person was issued 377,865 shares of the Issuer's common stock and 377,865 new warrants to purchase the Issuer's common stock at an exercise price of $18.00 (the "June Warrants"). The remaining 755,728 Original Warrants were surrendered in connection with the November Agreement described in footnote 3 below. The June Warrants expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). Prior to their surrender, the Original Warrants also had an expiration date of March 26, 2028. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $13.20 | IndirectBy Juv UK | 0 |
Reported balance
After 2024-11-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-11-27 · Disposition to issuer · Disposed 755,728 · Balance 0 F3: On November 27, 2024, pursuant to certain agreements entered into among the Issuer, the Reporting Person and Juv UK dated November 26, 2024 (the "November Agreement"), the Reporting Person purchased 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and, in connection therewith, surrendered the Original Warrants and was issued 377,865 warrants to purchase shares of the Issuer's common stock (the "New Warrants"). The New Warrants have an exercise price of $18.00 per warrant, expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). On January 31, 2025, in accordance with the November Agreement, the Reporting Person purchased another 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and was issued 377,865 additional New Warrants. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $18.00 | IndirectBy Juv UK | 377,864 |
Reported balance
After 2024-11-27 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-11-27 · Grant · Acquired 377,864 · Balance 377,864 F3: On November 27, 2024, pursuant to certain agreements entered into among the Issuer, the Reporting Person and Juv UK dated November 26, 2024 (the "November Agreement"), the Reporting Person purchased 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and, in connection therewith, surrendered the Original Warrants and was issued 377,865 warrants to purchase shares of the Issuer's common stock (the "New Warrants"). The New Warrants have an exercise price of $18.00 per warrant, expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). On January 31, 2025, in accordance with the November Agreement, the Reporting Person purchased another 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and was issued 377,865 additional New Warrants. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $18.00 | IndirectBy Juv UK | 755,728 |
Reported balance
After 2025-01-31 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-01-31 · Grant · Acquired 377,864 · Balance 755,728 F3: On November 27, 2024, pursuant to certain agreements entered into among the Issuer, the Reporting Person and Juv UK dated November 26, 2024 (the "November Agreement"), the Reporting Person purchased 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and, in connection therewith, surrendered the Original Warrants and was issued 377,865 warrants to purchase shares of the Issuer's common stock (the "New Warrants"). The New Warrants have an exercise price of $18.00 per warrant, expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). On January 31, 2025, in accordance with the November Agreement, the Reporting Person purchased another 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and was issued 377,865 additional New Warrants. |
Filing footnotes · ownership attribution and instrument terms
F1: As previously reported, on March 26, 2024, the Issuer (formerly known as "AgeX Therapeutics, Inc.") completed its merger transaction with, inter alia, Serina Therapeutics, Inc. (the "Merger"). Following the closing of the Merger, the Reporting Person held 1,889,323 shares of the Issuer's common stock, which shares are included in Column 5. These shares are held by the Reporting Person's wholly owned subsidiary, JuvVentures (UK) ("Juv UK"). Additional details about the Merger and the transactions described in this report can be found in the Issuer's and the Reporting Person's previous filings with the Commission.
F2: On June 6, 2024, the Reporting Person exercised 377,865 warrants at an exercise price of $13.20 per warrant (the "Original Warrants"), representing one-third of the of the Original Warrants, which were issued to the Reporting Person in connection with a warrant dividend effected on March 18, 2024, Upon such exercise, the Reporting Person was issued 377,865 shares of the Issuer's common stock and 377,865 new warrants to purchase the Issuer's common stock at an exercise price of $18.00 (the "June Warrants"). The remaining 755,728 Original Warrants were surrendered in connection with the November Agreement described in footnote 3 below. The June Warrants expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). Prior to their surrender, the Original Warrants also had an expiration date of March 26, 2028.
F3: On November 27, 2024, pursuant to certain agreements entered into among the Issuer, the Reporting Person and Juv UK dated November 26, 2024 (the "November Agreement"), the Reporting Person purchased 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and, in connection therewith, surrendered the Original Warrants and was issued 377,865 warrants to purchase shares of the Issuer's common stock (the "New Warrants"). The New Warrants have an exercise price of $18.00 per warrant, expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). On January 31, 2025, in accordance with the November Agreement, the Reporting Person purchased another 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and was issued 377,865 additional New Warrants.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 31, 2025 Filed Feb 3, 2025 21:01 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | GrantWarrants · Derivative | 377,864 | Not disclosed Strike: $18.00 | Not disclosed |
DisclosureSEC source: 0001104659-25-008610 · tm255065-1_4seq1.xml · derivative · entry 8 Juvenescence Ltd · CIK 0001724307 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Juv UK Disclosed balance after: 755,728 Underlying: Common Stock · 377,864 shares Expires not disclosed F3 · derivative.exercise_price: On November 27, 2024, pursuant to certain agreements entered into among the Issuer, the Reporting Person and Juv UK dated November 26, 2024 (the "November Agreement"), the Reporting Person purchased 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and, in connection therewith, surrendered the Original Warrants and was issued 377,865 warrants to purchase shares of the Issuer's common stock (the "New Warrants"). The New Warrants have an exercise price of $18.00 per warrant, expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). On January 31, 2025, in accordance with the November Agreement, the Reporting Person purchased another 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and was issued 377,865 additional New Warrants. F3 · price: On November 27, 2024, pursuant to certain agreements entered into among the Issuer, the Reporting Person and Juv UK dated November 26, 2024 (the "November Agreement"), the Reporting Person purchased 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and, in connection therewith, surrendered the Original Warrants and was issued 377,865 warrants to purchase shares of the Issuer's common stock (the "New Warrants"). The New Warrants have an exercise price of $18.00 per warrant, expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). On January 31, 2025, in accordance with the November Agreement, the Reporting Person purchased another 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and was issued 377,865 additional New Warrants. F3 · derivative.exercise_date: On November 27, 2024, pursuant to certain agreements entered into among the Issuer, the Reporting Person and Juv UK dated November 26, 2024 (the "November Agreement"), the Reporting Person purchased 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and, in connection therewith, surrendered the Original Warrants and was issued 377,865 warrants to purchase shares of the Issuer's common stock (the "New Warrants"). The New Warrants have an exercise price of $18.00 per warrant, expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). On January 31, 2025, in accordance with the November Agreement, the Reporting Person purchased another 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and was issued 377,865 additional New Warrants. F3 · derivative.expiration_date: On November 27, 2024, pursuant to certain agreements entered into among the Issuer, the Reporting Person and Juv UK dated November 26, 2024 (the "November Agreement"), the Reporting Person purchased 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and, in connection therewith, surrendered the Original Warrants and was issued 377,865 warrants to purchase shares of the Issuer's common stock (the "New Warrants"). The New Warrants have an exercise price of $18.00 per warrant, expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). On January 31, 2025, in accordance with the November Agreement, the Reporting Person purchased another 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and was issued 377,865 additional New Warrants. Read SEC document |
| January 31, 2025 Filed Feb 3, 2025 21:01 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | GrantCommon Stock | 500,000 | $10.00 | $5,000,000.00 |
DisclosureSEC source: 0001104659-25-008610 · tm255065-1_4seq1.xml · nonDerivative · entry 3 Juvenescence Ltd · CIK 0001724307 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Bu Juv UK Disclosed balance after: 3,267,188 F1 · balance_after: As previously reported, on March 26, 2024, the Issuer (formerly known as "AgeX Therapeutics, Inc.") completed its merger transaction with, inter alia, Serina Therapeutics, Inc. (the "Merger"). Following the closing of the Merger, the Reporting Person held 1,889,323 shares of the Issuer's common stock, which shares are included in Column 5. These shares are held by the Reporting Person's wholly owned subsidiary, JuvVentures (UK) ("Juv UK"). Additional details about the Merger and the transactions described in this report can be found in the Issuer's and the Reporting Person's previous filings with the Commission. F3 · balance_after: On November 27, 2024, pursuant to certain agreements entered into among the Issuer, the Reporting Person and Juv UK dated November 26, 2024 (the "November Agreement"), the Reporting Person purchased 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and, in connection therewith, surrendered the Original Warrants and was issued 377,865 warrants to purchase shares of the Issuer's common stock (the "New Warrants"). The New Warrants have an exercise price of $18.00 per warrant, expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). On January 31, 2025, in accordance with the November Agreement, the Reporting Person purchased another 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and was issued 377,865 additional New Warrants. Read SEC document |
| November 27, 2024 Filed Feb 3, 2025 21:01 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | GrantWarrants · Derivative | 377,864 | Not disclosed Strike: $18.00 | Not disclosed |
DisclosureSEC source: 0001104659-25-008610 · tm255065-1_4seq1.xml · derivative · entry 7 Juvenescence Ltd · CIK 0001724307 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Juv UK Disclosed balance after: 377,864 Underlying: Common Stock · 377,864 shares Expires not disclosed F3 · price: On November 27, 2024, pursuant to certain agreements entered into among the Issuer, the Reporting Person and Juv UK dated November 26, 2024 (the "November Agreement"), the Reporting Person purchased 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and, in connection therewith, surrendered the Original Warrants and was issued 377,865 warrants to purchase shares of the Issuer's common stock (the "New Warrants"). The New Warrants have an exercise price of $18.00 per warrant, expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). On January 31, 2025, in accordance with the November Agreement, the Reporting Person purchased another 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and was issued 377,865 additional New Warrants. F3 · derivative.exercise_date: On November 27, 2024, pursuant to certain agreements entered into among the Issuer, the Reporting Person and Juv UK dated November 26, 2024 (the "November Agreement"), the Reporting Person purchased 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and, in connection therewith, surrendered the Original Warrants and was issued 377,865 warrants to purchase shares of the Issuer's common stock (the "New Warrants"). The New Warrants have an exercise price of $18.00 per warrant, expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). On January 31, 2025, in accordance with the November Agreement, the Reporting Person purchased another 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and was issued 377,865 additional New Warrants. F3 · derivative.expiration_date: On November 27, 2024, pursuant to certain agreements entered into among the Issuer, the Reporting Person and Juv UK dated November 26, 2024 (the "November Agreement"), the Reporting Person purchased 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and, in connection therewith, surrendered the Original Warrants and was issued 377,865 warrants to purchase shares of the Issuer's common stock (the "New Warrants"). The New Warrants have an exercise price of $18.00 per warrant, expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). On January 31, 2025, in accordance with the November Agreement, the Reporting Person purchased another 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and was issued 377,865 additional New Warrants. Read SEC document |
| November 27, 2024 Filed Feb 3, 2025 21:01 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Disposition to issuerWarrants · Derivative | 755,728 | Not disclosed Strike: $13.20 | Not disclosed |
DisclosureSEC source: 0001104659-25-008610 · tm255065-1_4seq1.xml · derivative · entry 6 Juvenescence Ltd · CIK 0001724307 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Juv UK Disclosed balance after: 0 Underlying: Common Stock · 755,728 shares Expires not disclosed F3 · price: On November 27, 2024, pursuant to certain agreements entered into among the Issuer, the Reporting Person and Juv UK dated November 26, 2024 (the "November Agreement"), the Reporting Person purchased 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and, in connection therewith, surrendered the Original Warrants and was issued 377,865 warrants to purchase shares of the Issuer's common stock (the "New Warrants"). The New Warrants have an exercise price of $18.00 per warrant, expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). On January 31, 2025, in accordance with the November Agreement, the Reporting Person purchased another 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and was issued 377,865 additional New Warrants. F3 · derivative.exercise_date: On November 27, 2024, pursuant to certain agreements entered into among the Issuer, the Reporting Person and Juv UK dated November 26, 2024 (the "November Agreement"), the Reporting Person purchased 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and, in connection therewith, surrendered the Original Warrants and was issued 377,865 warrants to purchase shares of the Issuer's common stock (the "New Warrants"). The New Warrants have an exercise price of $18.00 per warrant, expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). On January 31, 2025, in accordance with the November Agreement, the Reporting Person purchased another 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and was issued 377,865 additional New Warrants. F3 · derivative.expiration_date: On November 27, 2024, pursuant to certain agreements entered into among the Issuer, the Reporting Person and Juv UK dated November 26, 2024 (the "November Agreement"), the Reporting Person purchased 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and, in connection therewith, surrendered the Original Warrants and was issued 377,865 warrants to purchase shares of the Issuer's common stock (the "New Warrants"). The New Warrants have an exercise price of $18.00 per warrant, expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). On January 31, 2025, in accordance with the November Agreement, the Reporting Person purchased another 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and was issued 377,865 additional New Warrants. Read SEC document |
| November 27, 2024 Filed Feb 3, 2025 21:01 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | GrantCommon Stock | 500,000 | $10.00 | $5,000,000.00 |
DisclosureSEC source: 0001104659-25-008610 · tm255065-1_4seq1.xml · nonDerivative · entry 2 Juvenescence Ltd · CIK 0001724307 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Juv UK Disclosed balance after: 2,767,188 F1 · balance_after: As previously reported, on March 26, 2024, the Issuer (formerly known as "AgeX Therapeutics, Inc.") completed its merger transaction with, inter alia, Serina Therapeutics, Inc. (the "Merger"). Following the closing of the Merger, the Reporting Person held 1,889,323 shares of the Issuer's common stock, which shares are included in Column 5. These shares are held by the Reporting Person's wholly owned subsidiary, JuvVentures (UK) ("Juv UK"). Additional details about the Merger and the transactions described in this report can be found in the Issuer's and the Reporting Person's previous filings with the Commission. F3 · balance_after: On November 27, 2024, pursuant to certain agreements entered into among the Issuer, the Reporting Person and Juv UK dated November 26, 2024 (the "November Agreement"), the Reporting Person purchased 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and, in connection therewith, surrendered the Original Warrants and was issued 377,865 warrants to purchase shares of the Issuer's common stock (the "New Warrants"). The New Warrants have an exercise price of $18.00 per warrant, expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). On January 31, 2025, in accordance with the November Agreement, the Reporting Person purchased another 500,000 shares of the Issuer's common stock at a purchase price of $10.00 per share and was issued 377,865 additional New Warrants. Read SEC document |
| June 06, 2024 Filed Feb 3, 2025 21:01 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | GrantWarrants · Derivative | 377,865 | Not disclosed Strike: $18.00 | Not disclosed |
DisclosureSEC source: 0001104659-25-008610 · tm255065-1_4seq1.xml · derivative · entry 5 Juvenescence Ltd · CIK 0001724307 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Juv UK Disclosed balance after: 377,865 Underlying: Common Stock · 377,865 shares Expires not disclosed F2 · price: On June 6, 2024, the Reporting Person exercised 377,865 warrants at an exercise price of $13.20 per warrant (the "Original Warrants"), representing one-third of the of the Original Warrants, which were issued to the Reporting Person in connection with a warrant dividend effected on March 18, 2024, Upon such exercise, the Reporting Person was issued 377,865 shares of the Issuer's common stock and 377,865 new warrants to purchase the Issuer's common stock at an exercise price of $18.00 (the "June Warrants"). The remaining 755,728 Original Warrants were surrendered in connection with the November Agreement described in footnote 3 below. The June Warrants expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). Prior to their surrender, the Original Warrants also had an expiration date of March 26, 2028. F2 · derivative.exercise_date: On June 6, 2024, the Reporting Person exercised 377,865 warrants at an exercise price of $13.20 per warrant (the "Original Warrants"), representing one-third of the of the Original Warrants, which were issued to the Reporting Person in connection with a warrant dividend effected on March 18, 2024, Upon such exercise, the Reporting Person was issued 377,865 shares of the Issuer's common stock and 377,865 new warrants to purchase the Issuer's common stock at an exercise price of $18.00 (the "June Warrants"). The remaining 755,728 Original Warrants were surrendered in connection with the November Agreement described in footnote 3 below. The June Warrants expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). Prior to their surrender, the Original Warrants also had an expiration date of March 26, 2028. F2 · derivative.expiration_date: On June 6, 2024, the Reporting Person exercised 377,865 warrants at an exercise price of $13.20 per warrant (the "Original Warrants"), representing one-third of the of the Original Warrants, which were issued to the Reporting Person in connection with a warrant dividend effected on March 18, 2024, Upon such exercise, the Reporting Person was issued 377,865 shares of the Issuer's common stock and 377,865 new warrants to purchase the Issuer's common stock at an exercise price of $18.00 (the "June Warrants"). The remaining 755,728 Original Warrants were surrendered in connection with the November Agreement described in footnote 3 below. The June Warrants expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). Prior to their surrender, the Original Warrants also had an expiration date of March 26, 2028. Read SEC document |
| June 06, 2024 Filed Feb 3, 2025 21:01 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionWarrants · Derivative | 377,865 | Not disclosed Strike: $13.20 | Not disclosed |
DisclosureSEC source: 0001104659-25-008610 · tm255065-1_4seq1.xml · derivative · entry 4 Juvenescence Ltd · CIK 0001724307 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Juv UK Disclosed balance after: 755,728 Underlying: Common Stock · 377,865 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: On June 6, 2024, the Reporting Person exercised 377,865 warrants at an exercise price of $13.20 per warrant (the "Original Warrants"), representing one-third of the of the Original Warrants, which were issued to the Reporting Person in connection with a warrant dividend effected on March 18, 2024, Upon such exercise, the Reporting Person was issued 377,865 shares of the Issuer's common stock and 377,865 new warrants to purchase the Issuer's common stock at an exercise price of $18.00 (the "June Warrants"). The remaining 755,728 Original Warrants were surrendered in connection with the November Agreement described in footnote 3 below. The June Warrants expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). Prior to their surrender, the Original Warrants also had an expiration date of March 26, 2028. F2 · derivative.exercise_date: On June 6, 2024, the Reporting Person exercised 377,865 warrants at an exercise price of $13.20 per warrant (the "Original Warrants"), representing one-third of the of the Original Warrants, which were issued to the Reporting Person in connection with a warrant dividend effected on March 18, 2024, Upon such exercise, the Reporting Person was issued 377,865 shares of the Issuer's common stock and 377,865 new warrants to purchase the Issuer's common stock at an exercise price of $18.00 (the "June Warrants"). The remaining 755,728 Original Warrants were surrendered in connection with the November Agreement described in footnote 3 below. The June Warrants expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). Prior to their surrender, the Original Warrants also had an expiration date of March 26, 2028. F2 · derivative.expiration_date: On June 6, 2024, the Reporting Person exercised 377,865 warrants at an exercise price of $13.20 per warrant (the "Original Warrants"), representing one-third of the of the Original Warrants, which were issued to the Reporting Person in connection with a warrant dividend effected on March 18, 2024, Upon such exercise, the Reporting Person was issued 377,865 shares of the Issuer's common stock and 377,865 new warrants to purchase the Issuer's common stock at an exercise price of $18.00 (the "June Warrants"). The remaining 755,728 Original Warrants were surrendered in connection with the November Agreement described in footnote 3 below. The June Warrants expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). Prior to their surrender, the Original Warrants also had an expiration date of March 26, 2028. Read SEC document |
| June 06, 2024 Filed Feb 3, 2025 21:01 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | Exercise / conversionCommon Stock | 377,865 | $13.20 | $4,987,818.00 |
DisclosureSEC source: 0001104659-25-008610 · tm255065-1_4seq1.xml · nonDerivative · entry 1 Juvenescence Ltd · CIK 0001724307 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Juv UK Disclosed balance after: 2,267,188 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: As previously reported, on March 26, 2024, the Issuer (formerly known as "AgeX Therapeutics, Inc.") completed its merger transaction with, inter alia, Serina Therapeutics, Inc. (the "Merger"). Following the closing of the Merger, the Reporting Person held 1,889,323 shares of the Issuer's common stock, which shares are included in Column 5. These shares are held by the Reporting Person's wholly owned subsidiary, JuvVentures (UK) ("Juv UK"). Additional details about the Merger and the transactions described in this report can be found in the Issuer's and the Reporting Person's previous filings with the Commission. F2 · balance_after: On June 6, 2024, the Reporting Person exercised 377,865 warrants at an exercise price of $13.20 per warrant (the "Original Warrants"), representing one-third of the of the Original Warrants, which were issued to the Reporting Person in connection with a warrant dividend effected on March 18, 2024, Upon such exercise, the Reporting Person was issued 377,865 shares of the Issuer's common stock and 377,865 new warrants to purchase the Issuer's common stock at an exercise price of $18.00 (the "June Warrants"). The remaining 755,728 Original Warrants were surrendered in connection with the November Agreement described in footnote 3 below. The June Warrants expire on March 26, 2028 and are immediately exercisable (with each warrant exercisable for one share of the Issuer's common stock). Prior to their surrender, the Original Warrants also had an expiration date of March 26, 2028. Read SEC document |
| April 25, 2023 Filed May 18, 2023 20:00 UTC | Serina Therapeutics, Inc. AGE · Entity 9581 | GrantWarrant to Purchase Common Stock · Derivative | 756,429 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0001104659-23-062241 · tm2312573-1_4seq1.xml · derivative · entry 1 Juvenescence Ltd · CIK 0001724307 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 756,429 Underlying: Common Stock · 756,429 shares Expires 2026-04-23 F1 · security: Warrants issued in connection with the draw of loan funds under an Amended and Restated Secured Convertible Promissory Note between the issuer and the reporting person. F2 · derivative.exercise_date: The warrants are exercisable for shares of the issuer's common stock upon issuance. Read SEC document |
| March 14, 2023 Filed Mar 22, 2023 20:20 UTC | Serina Therapeutics, Inc. AGE · Entity 9581 | GiftCommon Stock | 16,447,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-035606 · tm2310075-3_4seq1.xml · nonDerivative · entry 1 Juvenescence Ltd · CIK 0001724307 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction involved a transfer of securities to the reporting person's wholly owned subsidiary, Juvenescence US Corp. Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 12:01 UTC | Serina Therapeutics, Inc. AGE · Entity 9581 | GrantWarrant to Purchase Common Stock · Derivative | 801,924 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001104659-23-023041 · tm234525-2_4seq1.xml · derivative · entry 1 Juvenescence Ltd · CIK 0001724307 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 801,924 Underlying: Common Stock · 801,924 shares Expires 2026-02-15 F1 · security: Warrants issued in connection with the draw of loan funds under an Amended and Restated Secured Convertible Promissory Note between the issuer and the reporting person. F2 · derivative.exercise_date: The warrants are exercisable for shares of the issuer's common stock upon issuance. Read SEC document |
| February 07, 2023 Filed Feb 8, 2023 21:00 UTC | Serina Therapeutics, Inc. AGE · Entity 9581 | GrantWarrant to Purchase Common Stock · Derivative | 340,136 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0001104659-23-014515 · tm234525-1_4seq1.xml · derivative · entry 1 Juvenescence Ltd · CIK 0001724307 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,136 Underlying: Common Stock · 340,136 shares Expires 2026-01-25 F1 · security: Warrants issued in connection with the draw of loan funds under a Secured Convertible Promissory Note between the issuer and the reporting person. F2 · derivative.exercise_date: The warrants are exercisable for shares of the issuer's common stock upon issuance. Read SEC document |
| December 19, 2022 Filed Dec 19, 2022 21:55 UTC | Serina Therapeutics, Inc. AGE · Entity 9581 | GrantWarrant to Purchase Common Stock · Derivative | 847,457 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001104659-22-128296 · tm2232622-2_4seq1.xml · derivative · entry 1 Juvenescence Ltd · CIK 0001724307 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 847,457 Underlying: Common Stock · 847,457 shares Expires 2025-12-14 F1 · security: Warrants issued in connection with the draw of loan funds under a Secured Convertible Promissory Note between the issuer and the reporting person. F2 · derivative.exercise_date: The warrants are exercisable for shares of the issuer's common stock upon issuance. Read SEC document |
| October 26, 2022 Filed Oct 27, 2022 20:05 UTC | Serina Therapeutics, Inc. AGE · Entity 9581 | GrantWarrant to Purchase Common Stock · Derivative | 362,318 | $0.00 Strike: $0.69 | $0.00 |
DisclosureSEC source: 0001104659-22-111999 · tm2229063-1_4seq1.xml · derivative · entry 1 Juvenescence Ltd · CIK 0001724307 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 362,318 Underlying: Common Stock · 362,318 shares Expires 2025-10-21 F1 · security: Warrants issued in connection with the draw of loan funds under a Secured Convertible Promissory Note between the issuer and the reporting person. F2 · derivative.exercise_date: The warrants are exercisable for shares of the issuer's common stock upon issuance. Read SEC document |
| August 24, 2022 Filed Aug 24, 2022 23:19 UTC | Serina Therapeutics, Inc. AGE · Entity 9581 | GrantWarrant to Purchase Common Stock · Derivative | 746,380 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0001104659-22-094116 · tm2224221-1_4seq1.xml · derivative · entry 1 Juvenescence Ltd · CIK 0001724307 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 746,380 Underlying: Common Stock · 746,380 shares Expires 2025-08-15 F1 · security: Warrants issued in connection with the draw of loan funds under a Secured Convertible Promissory Note between the issuer and the reporting person. F2 · derivative.exercise_date: The warrants are exercisable for shares of the issuer's common stock upon issuance. Read SEC document |
| July 11, 2022 Filed Aug 24, 2022 23:17 UTC | Serina Therapeutics, Inc. AGE · Entity 9581 | GrantWarrant to Purchase Common Stock · Derivative | 703,234 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001104659-22-094115 · tm2224221-2_4seq1.xml · derivative · entry 1 Juvenescence Ltd · CIK 0001724307 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 703,234 Underlying: Common Stock · 703,234 shares Expires 2025-06-06 F1 · security: Warrants issued in connection with the draw of loan funds under a Secured Convertible Promissory Note between the issuer and the reporting person. F2 · derivative.exercise_date: The warrants are exercisable for shares of the issuer's common stock upon issuance. Read SEC document |
| April 14, 2022 Filed Apr 15, 2022 00:47 UTC | Serina Therapeutics, Inc. AGE · Entity 9581 | GrantWarrant to Purchase Common Stock · Derivative | 568,440 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0001104659-22-046163 · tm2212100-1_4seq1.xml · derivative · entry 1 Juvenescence Ltd · CIK 0001724307 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 568,440 Underlying: Common Stock · 568,440 shares Expires 2025-04-04 F1 · security: Warrants issued in connection with the draw of loan funds under a Secured Convertible Promissory Note between the issuer and the reporting person. F2 · derivative.exercise_date: The warrants are exercisable for shares of the issuer's common stock upon issuance. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 21:18 UTC | Serina Therapeutics, Inc. AGE · Entity 9581 | GrantWarrant to Purchase Common Stock · Derivative | 5,230,768 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001104659-22-032900 · tm226683-2_4seq1.xml · derivative · entry 1 Juvenescence Ltd · CIK 0001724307 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,230,768 Underlying: Common Stock · 5,230,768 shares Expires 2025-02-13 F1 · security: Warrants issued in connection with the draw of loan funds under a Secured Convertible Promissory Note between the issuer and the reporting person. F2 · derivative.exercise_date: The warrants are exercisable for shares of the issuer's common stock upon issuance. Read SEC document |
| February 03, 2022 Filed Feb 14, 2022 21:42 UTC | Serina Therapeutics, Inc. AGE · Entity 9581 | PurchaseWarrant to Purchase Common Stock · Derivative | 308,565 | $0.00 Strike: $0.81 | $0.00 |
DisclosureSEC source: 0001104659-22-022985 · tm226683-1_4seq1.xml · derivative · entry 1 Juvenescence Ltd · CIK 0001724307 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,565 Underlying: Common Stock · 308,565 shares Expires 2025-01-30 F1 · security: Warrants issued in connection with the draw of loan funds under a Secured Convertible Facility Agreement between the issuer and the reporting person. F2 · derivative.exercise_date: The warrants are exercisable for shares of the issuer's common stock upon issuance. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 21:16 UTC | Serina Therapeutics, Inc. AGE · Entity 9581 | PurchaseWarrant to Purchase Common Stock · Derivative | 263,852 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0001104659-21-016679 · tm215727-1_4seq1.xml · derivative · entry 1 Juvenescence Ltd · CIK 0001724307 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,852 Underlying: Common Stock · 263,852 shares Expires 2024-01-25 F1 · security: Warrants issued in connection with the draw of loan funds under a Secured Convertible Facility Agreement between the issuer and the reporting person. F2 · derivative.exercise_date: The warrants are exercisable for shares of the issuer's common stock upon issuance. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 21:21 UTC | Serina Therapeutics, Inc. AGE · Entity 9581 | PurchaseWarrant to Purchase Common Stock · Derivative | 328,947 | $0.00 Strike: $1.52 | $0.00 |
DisclosureSEC source: 0001104659-21-003453 · tm212934-1_4seq1.xml · derivative · entry 1 Juvenescence Ltd · CIK 0001724307 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,947 Underlying: Common Stock · 328,947 shares Expires 2024-01-03 F1 · security: Warrants issued in connection with the draw of loan funds under a Secured Convertible Facility Agreement between the issuer and the reporting person. F2 · derivative.exercise_date: The warrants are exercisable for shares of the issuer's common stock upon issuance. Read SEC document |
| November 11, 2020 Filed Nov 19, 2020 22:29 UTC | Serina Therapeutics, Inc. AGE · Entity 9581 | PurchaseWarrant to Purchase Common Stock · Derivative | 280,898 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0001104659-20-127424 · a4.xml · derivative · entry 1 Juvenescence Ltd · CIK 0001724307 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,898 Underlying: Common Stock · 280,898 shares Expires 2023-11-08 F1 · security: Warrants issued in connection with the draw of loan funds under a Secured Convertible Facility Agreement between the issuer and the reporting person. F2 · derivative.exercise_date: The warrants are exercisable for shares of the issuer's common stock upon issuance. Read SEC document |
| October 02, 2020 Filed Oct 6, 2020 21:37 UTC | Serina Therapeutics, Inc. AGE · Entity 9581 | PurchaseWarrant to Purchase Common Stock · Derivative | 588,235 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001104659-20-112748 · a4.xml · derivative · entry 1 Juvenescence Ltd · CIK 0001724307 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 588,235 Underlying: Common Stock · 588,235 shares Expires 2023-09-14 F1 · security: Issued in connection with Loan Facility Agreement. F2 · derivative.exercise_date: Warrant shares are exercisable as of the date of issuance of the warrant. Read SEC document |
| July 27, 2020 Filed Jul 30, 2020 12:18 UTC | Serina Therapeutics, Inc. AGE · Entity 9581 | PurchaseWarrant to Purchase Common Stock · Derivative | 375,939 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0000908662-20-000143 · edgar.xml · derivative · entry 1 Juvenescence Ltd · CIK 0001724307 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,939 Underlying: Common Stock · 375,939 shares Expires 2023-07-26 F1 · security: Issued in connection with Loan Facility Agreement. F1 · price: Issued in connection with Loan Facility Agreement. F2 · derivative.exercise_date: Warrant shares are exercisable as of the date of issuance of the warrant. Read SEC document |
| June 11, 2020 Filed Jun 16, 2020 20:01 UTC | Serina Therapeutics, Inc. AGE · Entity 9581 | PurchaseWarrant to Purchase Common Stock · Derivative | 541,125 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0000908662-20-000130 · edgar.xml · derivative · entry 2 Juvenescence Ltd · CIK 0001724307 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 541,125 Underlying: Common Stock · 541,125 shares Expires 2023-06-10 F1 · security: Issued in connection with Loan Facility Agreement. F1 · price: Issued in connection with Loan Facility Agreement. F2 · derivative.exercise_date: Warrant shares are exercisable as of the date of issuance of the warrant. Read SEC document |
| May 15, 2020 Filed Jun 16, 2020 20:01 UTC | Serina Therapeutics, Inc. AGE · Entity 9581 | PurchaseWarrant to Purchase Common Stock · Derivative | 714,285 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0000908662-20-000130 · edgar.xml · derivative · entry 1 Juvenescence Ltd · CIK 0001724307 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 714,285 Underlying: Common Stock · 714,285 shares Expires 2023-05-14 F1 · security: Issued in connection with Loan Facility Agreement. F1 · price: Issued in connection with Loan Facility Agreement. F2 · derivative.exercise_date: Warrant shares are exercisable as of the date of issuance of the warrant. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:02 UTC | Serina Therapeutics, Inc. AGE · Entity 9581 | PurchaseWarrant to Purchase Common Stock · Derivative | 268,817 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0000908662-20-000071 · edgar.xml · derivative · entry 1 Juvenescence Ltd · CIK 0001724307 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,817 Underlying: Common Stock · 268,817 shares Expires 2023-03-31 F1 · security: Issued in connection with Loan Facility Agreement. F1 · price: Issued in connection with Loan Facility Agreement. F2 · derivative.exercise_date: Warrant shares are fully exercisable as of the date of issuance of the warrant. Read SEC document |
| August 13, 2019 Filed Aug 15, 2019 18:50 UTC | Serina Therapeutics, Inc. AGE · Entity 9581 | PurchaseWarrant to Purchase Common Stock · Derivative | 150,000 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0000908662-19-000177 · edgar.xml · derivative · entry 2 Juvenescence Ltd · CIK 0001724307 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2022-08-12 F1 · price: Issued in connection with Loan Facility Agreement. F2 · derivative.exercise_date: Warrant shares are fully exercisable as of the date of issuance of the warrant. Read SEC document |
| August 13, 2019 Filed Aug 15, 2019 18:50 UTC | Serina Therapeutics, Inc. AGE · Entity 9581 | PurchaseCommon Stock | 19,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000908662-19-000177 · edgar.xml · nonDerivative · entry 1 Juvenescence Ltd · CIK 0001724307 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,419,000 F1 · price: Issued in connection with Loan Facility Agreement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.